Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy

Diabetes Care

Volumn 38, Issue 5, 2015, Pages 883-890

  Panduru, Nicolae M ^a,b,c   Saraheimo, Markku ^b,c,d   Forsblom, Carol ^b,c,d   Thorn, Lena M ^b,c,d   Gordin, Daniel ^b,c,d   Wadén, Johan ^b,c,d   Tolonen, Nina ^b,c,d   Bierhaus, Angelika ^e   Humpert, Per M ^f   Groop, Per Henrik ^b,c,d,g  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Stoffwechselzentrum Rhein Pfalz   (Germany)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TUBULE DAMAGE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREDICTIVE VALUE; PROTEIN URINE LEVEL; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

ADIPONECTIN; ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE;

EID: 84946902245     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2276     Document Type: Article

References (40)

1. Groop PH, Thomas MC, Moran JL, et al, .; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
2. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-289
3. Li FY, Cheng KK, Lam KS, Vanhoutte PM, Xu A. Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol (Oxf) 2011;203:167-180
4. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008;118:1645-1656
5. Shen YY, Peake PW, Charlesworth JA. Review article: adiponectin: its role in kidney disease. Nephrology (Carlton) 2008;13:528-534
6. von Eynatten M, Liu D, Hock C, et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 2009;58:2093-2099
7. Saraheimo M, Forsblom C, Fagerudd J, et al, .; FinnDiane Study Group. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005;28:1410-1414
8. Saraheimo M, Forsblom C, Thorn L, et al, .; FinnDiane Study Group. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008;31:1165-1169
9. Fujita H, Morii T, Koshimura J, et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006;53:745-752
10. Thorn LM, Forsblom C, Wadén J, et al, .; Finnish Diabetic Nephropathy (FinnDiane) Study Group. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2009;32:950-952
11. Thorn LM, Forsblom C, Fagerudd J, et al, .; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005;28:2019-2024
12. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003;46:1402-1407
13. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406
14. Hoybye C, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol 2004;151:457-461
15. Panduru NM, Forsblom C, Saraheimo M, et al, .; FinnDiane Study Group. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013;36:2077-2083
16. Pintilie M. An introduction to competing risks analysis. Rev Esp Cardiol 2011;64:599-605 [in Spanish]
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
18. O'Brien R. A caution regarding rules of thumb for variance inflation factors. Qual Quant 2007;41:673-690
19. D'Agostino RB, Belanger A, D'Agostino RB Jr. A suggestion for using powerful and informative tests of normality. Am Stat 1990;44:316-321
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845
21. Pencina MJ, D'Agostino RBS Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212
22. Pencina MJ, D'Agostino RBS Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21
23. Choodari-Oskooei B, Royston P, Parmar MK. A simulation study of predictive ability measures in a survival model I: explained variation measures. Stat Med 2012;31:2627-2643
24. Jorsal A, Petersen EH, Tarnow L, et al. Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. J Diabetes Complications 2013;27:604-608
25. Forsblom CM, Groop PH, Ekstrand A, Groop LC. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 1992;305:1051-1053
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
27. Levey AS, Stevens LA, Schmid CH, et al, .; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
28. Forsblom C, Moran J, Harjutsalo V, et al, .; FinnDiane Study Group. Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 2014;37:2334-2342
29. Koshimura J, Fujita H, Narita T, et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 2004;316:165-169
30. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17:2100-2105
31. Karalliedde J, Viberti G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol 2010;21:2020-2027
32. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol 2009;5:397-406
33. Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007;27:1910-1917
34. Morii T, Fujita H, Narita T, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 2003;17:11-15
35. Lee YJ, Cho S, Kim SR. The association between serum adiponectin levels and nutritional status of hemodialysis patients. Ren Fail 2011;33:506-511
36. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946
37. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-529
38. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998;8:335-338
39. Leth H, Andersen KK, Frystyk J, et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab 2008;93:3186-3191
40. Kopf S, Oikonomou D, von Eynatten M, et al. Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes. Acta Diabetol 2014;51:479-489